OBJECTIVE: The overall aims of the ADDITION study are to evaluate whether screening for prevalent undiagnosed Type 2 diabetes is feasible, and whether subsequent optimised intensive treatment of diabetes, and associated risk factors, is feasible and bene®cial. DESIGN: Population-based screening in three European countries followed by an open, randomised controlled trial. SUBJECTS AND METHODS: People aged 40 ± 69 y in the community, without known diabetes, will be offered a random capillary blood glucose screening test by their primary care physicians, followed, if equal to or greater than 5.5 mmolal, by fasting and 2-h post-glucose-challenge blood glucose measurements. Three thousand newly diagnosed patients will subsequently receive conventional treatment (according to current national guidelines) or intensive multifactorial treatment (lifestyle advice, prescription of aspirin and ACE-inhibitors, in addition to protocol-driven tight control of blood glucose, blood pressure and cholesterol). Patients allocated to intensive treatment will be further randomised to centre-speci®c interventions to motivate adherence to lifestyle changes and medication. Duration of follow-up is planned for 5 y. Endpoints will include mortality, macrovascular and microvascular complications, patient health status and satisfaction, process-of-care indicators and costs.
Introduction
The aim of this paper is to describe the underlying rationale and proposed methods of the ADDITION study.
Type 2 diabetes meets many of the criteria for suitability for screening. 1 ± 3 It is increasingly common 4, 5 and is associated with a substantial burden of premature mortality, morbidity, suffering and ®nancial cost, both through its macrovascular and microvascular complications. 6 When people ®rst develop diabetes, either they have no symptoms, or if they do, they are frequently unable to recognise them. 7 Half of those meeting the diagnostic criteria for diabetes are undiagnosed 8 and extrapolation of the association between prevalence of retinopathy and duration of disease implies that diagnostic criteria might be met up to 12 y before clinical recognition. 9 ± 11 When patients are diagnosed 25% already have established retinopathy, 12 half have clinical evidence of diabetic tissue damage, 13 and many exhibit additional adverse cardiovascular risk factors. 12, 14 Furthermore, the options for treatment of hyperglycaemia in people with diabetes diagnosed clinically, and the effectiveness of these options are limited. 15 A growing body of evidence suggests that earlier detection and treatment of hyperglycaemia and related metabolic abnormalities may be bene®cial. The degree and duration of hyperglycaemia are associated with the development of microvascular complications. 16 Hyperglycaemia is also associated with the development of macrovascular disease. 17 The risk of complications can be reduced by intensive treatment of hyperglycaemia 15, 18 and more substantially through reduction of associated cardiovascular risk factors among people with clinically diagnosed disease. from intensive treatment of cardiovascular risk factors. 14, 20, 24 Indeed, the results of recent trials suggest that much of the potential bene®t of detection of undiagnosed diabetes is likely to accrue from intensive management of several cardiovascular risk factors as well as hyperglycaemia. 21, 22 It also seems that patients who are given the label of diabetes may bene®t from becoming involved in a more organised and effective system of risk factor management. 25, 26 However, the bene®ts of initiation of intensive treatment, with newer therapies and stricter management targets, among people with diabetes detected by screening, have not been quanti®ed.
There are also few data on the costs, both economic and psychological, of screening. Cost-effectiveness has been modelled using data from existing trials of treatment effectiveness and observational studies. 9, 27, 28 The conclusions of these studies are highly dependent upon certain crucial assumptions, and reach different conclusions about whether screening should be undertaken and which sub-groups could potentially bene®t. None of the studies include more recent trial evidence. Nevertheless, screening is now recommended by the American Diabetes Association. 29 Intensive management of diabetes and cardiovascular risk includes changes in behaviours such as smoking, physical activity, food choice and taking medication. Previous health promoting interventions in primary care, aimed at reducing cardiovascular risk, have produced modest bene®ts. 30 Patients also ®nd taking regular medication dif®cult, particularly for multiple drugs in asymptomatic conditions. 31 It is unclear whether additional interventions, based on theory and evidence from psychology, 32 ± 34 and studies of consultation skills, 35 ± 37 designed to facilitate and maintain changes in behaviour (including medication adherence) could be cost-effective among screen-detected cases.
Type 2 diabetes is increasingly diagnosed and managed in primary care, 38 and there is growing evidence that family practitioners are able to provide standards of care as good as that achieved in hospital outpatient departments. 39, 40 The overall aims of ADDITION (Anglo-DanishDutch Study of Intensive Treatment In People with Screen Detected Diabetes in Primary Care) are to evaluate whether screening for prevalent undiagnosed Type 2 diabetes is feasible, and whether subsequent optimised intensive treatment of the disease, and associated risk factors, is feasible and bene®cial.
Design and methods
The ADDITION study in Type 2 diabetes will consist of two phases: a screening study and a subsequent treatment study. In the screening study, we will evaluate the feasibility and results of three similar approaches to identifying people with undiagnosed Type 2 diabetes. Following completion of the screening study, the treatment study will compare the effects of standard treatment according to national guidelines, with intensive multifactorial therapy on mortality, macrovascular and microvascular disease. We will also assess the impact of treatment on patients' health status, quality of life, treatment satisfaction and health service use.
Screening study
In Denmark, primary care physicians participating in the study will send diabetes-related information to all individuals aged 40 ± 69 y enrolled in their practice. The information will deal with risk factors for Type 2 diabetes, and an accompanying letter and questionnaire will encourage individuals at high risk of diabetes to contact their physician for a blood glucose screening test. The questionnaire includes items on risk factors; symptoms of hyperglycaemia; family history of Type 2 diabetes; obesity; and previous cardiovascular disease, hypertension or dyslipidaemia. Criteria for contacting the physician will be chosen to encompass at least 75% of previously undiagnosed people with diabetes through examination of no more than 20% of the population receiving information.
In England, a simple previously validated risk score, based on routine general practice data (age, gender, prescribed medication and body mass index), 41 will be used to identify people at high risk of having prevalent undiagnosed diabetes from their computerised medical records. The score should enable identi®cation of 80% of those with undiagnosed diabetes through blood glucose testing of approximately 30%. 41 In The Netherlands all patients aged 40 ± 69 y, without known diabetes, in participating practices will be offered a screening test.
In all three countries random capillary blood glucose will be measured in general practice using a HemoCue. 42 If the random capillary blood glucose is less than 5.5 mmolal the person is told that diabetes is highly unlikely. If the random blood glucose is equal to or greater than 5.5 mmolal, the person will be invited to attend for a fasting capillary blood glucose, and if needed, a 2-h post-glucose-challenge measurement (OGTT), as determined by the algorithm in Figure 1 . The cut-off value of 5.5 mmolal will be reviewed after testing the ®rst 500 people and assessing the number requiring a second visit for a fasting sample. Individuals diagnosed with Type 2 diabetes will be asked to complete baseline measures including quality of life, health utility and self-perceived health.
Diagnostic criteria for Type 2 diabetes will follow current World Health Organization guidelines 43 ( Figure 1) . The algorithm differentiates individuals with Type 2 diabetes from those with impaired glucose tolerance and impaired fasting glycaemia, who will not be included in the treatment study.
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Patients previously diagnosed with diabetes, or treated with blood glucose lowering agents will be excluded. Outcome measures for the screening study are listed in Table 1 . These include measures of epidemiology and the performance of the screening campaign, the objective health status of patients newly identi®ed by the campaign, its feasibility as reported by the primary care physician, and the costs of such a programme.
We will also assess the broader impact of the information campaign by interviewing and sending questionnaires to a number of people who: (a) received the information but did not respond (for any reason); (b) contacted their physician and were not diagnosed with Type 2 diabetes; and (c) contacted their physician and were newly identi®ed with Type 2 diabetes. The interviews and subsequent analysis will explore the psychosocial aspects of identifying an at risk population and conducting a screening campaign for Type 2 diabetes.
Treatment study
Patients newly identi®ed with Type 2 diabetes will be invited to enter the ADDITION treatment study. This will compare the long-term effects of standard treatment with that of intensive multifactorial treatment, on key endpoints of mortality and morbidity. The study will be a pragmatic open, multicentre, randomised controlled trial with a duration of follow-up of 5 y.
All patients newly diagnosed with Type 2 diabetes in the screening study will be eligible to participate, unless they are found to have: contraindications or intolerance to study medication; a history of alcoholism, drug abuse, psychosis or other emotional problems that are likely to invalidate informed consent or adherence to treatment; malignant disease with a poor prognosis; or are pregnant or lactating. Informed consent will be sought and obtained from all patients and the study will be performed in accordance with the Declaration of Helsinki.
General practices will be randomised into two groups: the conventional therapy group will give standard care according to broadly similar national recommendations 44 ± 47 for the management of Type 2 diabetes and prevention of cardiovascular disease. The other group will receive education and training in the provision of intensive multifactorial treatment. The intensive therapy will include prescription of aspirin, lifestyle advice (concerning diet, physical activity and tobacco consumption) and stepwise increases in drug treatment of blood glucose, blood pressure and lipids according to strict targets as shown in Figure 2 . Within the intensive group, a further randomisation will allocate some patients to country-speci®c interventions concerned with motivating adherence to lifestyle changes and medication. This intervention, delivered either by a trained facilitator (England and The Netherlands) or through training of practitioners (Denmark), will be based on a client-centred, nondirective counselling style to help patients explore and resolve ambivalence and stimulate lifestyle changes, appropriate diabetes self-care and adherence to medical treatment. 35 ,36 Figure 1 Outline of algorithm for diagnosis for Type 2 diabetes using HemoCue for immediate measurement of capillary whole blood glucose. Recommendations on drug choices in Figure 2 are based on balancing treatment effect, side-effects and cost Ð the main priority being achievement of treatment targets with a¯exible lifestyle and low rates of side-effects such as hypoglycaemia and weight gain. The ®nal decision on choice of medication will be determined by the individual doctor and patient.
Initial therapies will be adjusted at 2 to 4-weekly intervals until targets are reached (thereafter every 3 months). When the maximum daily dose of an agent is reached the next treatment step will be made. Blood pressure, blood glucose, haemoglobin A 1c and body weight will be measured by practitioners at least quarterly throughout the study. In addition, urinary albumin and creatinine, cholesterol (total, LDL and HDL) and triglycerides will be measured annually, at which time an electrocardiogram, foot examination and eye examination will also be performed. Questionnaires will be used to assess patient health status and treatment satisfaction.
Endpoints of the treatment study are given in Table  2 . These include measures of mortality and morbidity; macrovascular and microvascular complications of diabetes; measures of metabolic and hypertensive control; and endpoints related to the process of care.
Sample size and statistical power
The expected event rate in the treatment study, based on levels of risk in the conservative-treatment arm of the UKPDS, is 3% annually for the combined endpoint of all-cause mortality, nonfatal myocardial infarction, stroke or amputation. 15 We calculate that a sample size of 1350 patients in the treatment study will allow the detection of a 30% relative risk The ADDITION study T Lauritzen et al reduction in the intervention group at a signi®cance level of 5%. To allow for the effects of clustering, approximately 3000 patients will be included in total.
Timescale
The screening study will begin in late 2000. Patients will be enrolled into the treatment study following diagnosis in the screening study: thus the treatment study will proceed concurrently with the evaluation phase of the screening study, extending until the end of 2001. A duration of follow-up of 5 y means that the ®nal study visit will occur during 2006.
Concluding remarks
Ideally, our goal is to prevent Type 2 diabetes, but for those who do develop the condition, we must ensure that they receive the best available treatment as soon as possible. Many people have undetected Type 2 diabetes, who we often see when they present with late diabetic complications. As with all screening programmes there is a balance between the potential bene®ts and psychological, physical and economic costs. This balance is particularly precarious when treatments are intensive, lifelong and expensive. The ADDITION study will inform judgements about these issues.
The results of the study will be of immediate relevance to policy decisions about screening for diabetes, and subsequent treatment internationally. The results of the sub-study will inform approaches to health promotion, to the management of chronic disease and risk, and to strategies to support adherence.
